We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Eco Animal Health Group Plc | EAH | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.50 | -0.40% | 125.00 | 08:06:10 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 125.50 | 125.00 | 125.50 | 125.00 | 125.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| Final | GBP | 0.01 | 23/09/2021 | 24/09/2021 | 22/10/2021 | |
| 19/06/2019 | Interim | GBP | 0.0704 | 26/09/2019 | 27/09/2019 | 16/10/2019 |
| Top Posts |
|---|
Posted at 07/4/2024 08:03 by cerrito Citywire summarizes the views of Shorequote Vet pharmaceutical group Eco Animal Health (EAH) has potential locked in its pipeline and is driving forward its core business with its latest disposal, says Shore Capital. Analyst Sean Conroy retained his ‘buy’ recommendation and ‘fair value’ target price of 175p on the stock, which softened 0.4% to 84.7p yesterday after the disposal of its non-core ECOmectin Horsepaste product line to its manufacturing partner for €1.3m. Conroy said the disposal shows that the group is focused on ‘driving forwards its core business of treatments and preventatives for pigs and poultry’. Shares in the business are trading on embedded value to pre-tax profit ratio of 5.8 times full-year 2024 and 5.1 times full-year 2024, which Conroy said was a ‘sizeable discount to animal health peers on 12 times and 11 times, respectively’. Sentiment has improved on the back of a positive trading update, but it has further to go if there is to be clarity on performance for the year at the next update. Conroy said there is ‘growth potential’ in the pipeline which means Eco Animal Health should ‘trade closer to the peer group average’. ‘Securing regulatory approvals for its mycoplasma poultry vaccines should provide a catalyst to allow more value to be ascribed to the pipeline,’ he said. ‘However, when discounting the dynamics of the development pipeline from our model, we still value the underlying commercial business at 150p, and, hence, we see a good buying opportunity from both a growth and value perspective.’ Next: SSP enjoying ongoing momentum |
Posted at 23/3/2024 14:26 by cerrito I found this on Citywirequote Vet pharmaceutical group Eco Animal Health (EAH) delivered a ‘reassuringly positive’ trading update and is offering both growth and value, says Shore Capital. Analyst Sean Conroy retained his ‘buy’ recommendation and a ‘fair value’ target price of 175p on the stock, which climbed 2.9%, or 2.5p, to 88p yesterday after ‘delivering robust growth in the current environment’ owing to its ‘commercial prowess’. Although the group has not been immune from recent weakness in pork prices it has demonstrated ‘a high degree of resilience to the ongoing lull in the hog cycle’. Conroy said the shares are trading on an embedded value to pre-tax earnings ratio of 5.9 times for 2025 and 5.3 times for 2025, which is a ‘sizeable discount to animal health peers on 12 times and 11 times, respectively’. He said the stock should trade closer to peers, inferring 100% upside to the share price. ‘Securing regulatory approvals for its Mycoplasma poultry vaccines in the first half 2025 should provide a catalyst to allow more value to be ascribed to the pipeline,’ he said. ‘However, when discounting the dynamics of the development pipeline from our model, we still value the underlying commercial business at 150p and hence, we see a good buying opportunity from both a growth and value perspective.’ |
Posted at 19/3/2024 21:25 by cerrito I am always interested in voter turnout at SGM and AGM of AIM companies to see how engaged shareholders are. Pretty much at EAH as 40m of the 67m shares were voted for routine and noncontroversial motions. |
Posted at 15/3/2024 11:58 by pugugly 1 year breakout DOWN. Skids really under EAH.p/ratio high and PEG too high for my liking. Plus of course political risk in main market. Anyone like to call the bottom? |
Posted at 17/2/2024 17:26 by cerrito I see the price has drifted down in the last few days with both Wednesday and Friday busy by EAH standards.I note last year we had a TU on March 8th and the year before on March 15th and am going on the basis that we will have one in the first half of this March. |
Posted at 13/1/2024 18:29 by cerrito Saw this on Citywire this week.quote Vet pharmaceutical group Eco Animal Health (EAH) had a challenging 2023 and there is ‘significant value on offer’, says Shore Capital. Analyst Sean Conroy reiterated his ‘buy recommendation on the stock, which was trading at 109p on Monday. It had a difficult 2023 due to its primary customer base, pork producers, dealing with depressed hog prices and elevated feed costs. ‘Despite this Eco Animal Health has delivered decent growth and continued to gain share with (pig disease treatment) Aivlosin, an impressive feat in our view, and certainly one that helps speak to its commercial prowess,’ said Conroy. This year, Conroy said that there is ‘ample scope for Eco Animal Health to sustain sales momentum and, given the strength of the performance in the first half, potentially beat our full-year 2024 forecasts’. ‘The latest set of interim results have helped to reaffirm our conviction that there is still significant value on offer from Eco Animal Health’s core, commercial business, and additional upside to be realised from its R&D pipeline.’ |
Posted at 08/1/2024 07:35 by ariane 8 January 2024ECO Animal Health Group plc ("ECO" or the "Company") Disposal of Freehold Properties ECO Animal Health Group plc (AIM: EAH) announces that on 5 January 2024 the Company completed the sale of its freehold property in New Malden, Surrey. This was the former registered office of the Company and following relocation of all functions to its office in Southgate, London, the office was surplus and unused. The net consideration received for the sale of this property was GBP831,454. The carrying value of the property was GBP565,000. Additionally, on 28 November 2023, the Company's freehold property at Western Road, Mitcham was sold to its long term occupier (an education charity) for net consideration of GBP227,000. This matched its carrying value and the previous rent payable was a peppercorn. The total cash received from these two property sales was GBP1,058,454 after fees and expenses. The Board intends to use the majority of the net proceeds to advance the growth aspirations of ECO. In due course, the Board also intends to use some of the proceeds to purchase ordinary shares of the Company in the market to cover possible future vesting of employee share-based incentives including share options, long term incentive plans and the deferred bonus scheme. In order to carry out such market purchases, the Company will need to seek approval from shareholders in a general meeting. |
Posted at 05/12/2023 10:21 by mr macgregor You can see why EAH are deflecting from China. |
Posted at 07/11/2023 20:47 by cerrito Yes,PUGUGLY,I saw that and here is the linkThey mention a company called Muyuan whose shares are down 20pc this year and had to pull a listing on the Zurich stock exchange. I have to say EAH has been out of sight out of mind for me. I agree that at macro level is not good news for EAH, although the article does reiterate what we have learnt before that small producers are being squeezed out in favour of larger ones which should help EAH in the long term. I have registered for the Thursday presentation. I wondered if we were going to get the interims on Thursday but probably they will come out in 2/3 weeks time nd they are often flagged in advance. |
Posted at 13/7/2023 16:51 by cerrito A good and professional presentation in the ED webinar and questions well answered.I would recommend people to watch it.I note strong H2 and strong start for the current FY, their point on geographic diversity and their promising new product pipeline and the fact that they have sidestepped the UK regulatory authorities and are dealing with the USDA, who they say are efficient and speedy. Also good to get steer that reasonable to think that we can get £4m of dividends this FY from the wholly owned sub in China. That said while I have no intention of selling I am reluctant to buy more. By my standards I have more than enough invested here. I had a rush of blood to the head 5 years ago to the month and made my first purchase at 540. My current inprice is 170. I do not feel comfortable that I understand the industry well enough and the competitive landscape. In their note ED do address these issues. There is the China situation. If anything were to happen with Taiwan all bets are off, especially as all their secret sauce is manufactured there. Perhaps naively I do not see them as having issues domestically with the Chinse government as what EAH does is in line with the interests of the CCP namely keep pork/poultry prices down. The main issue is that at least from the current product lines, I cannot see where growth is coming from,and as Topvest says the PE is very generous. Indeed as per Singers even in FY26 it will be 51x. Ps I am having difficulty in sharing the excitement of EAH in their new products and R&D programme. Trying to work out why I have this blind spot. One reason is that a company looking to bring a new medicine in the human health field will tell us information on how many people in a given country suffer from the disease and some idea of the monetary figures involved. There will often be a comment on what their new proposed drug/vaccine brings to the party compared to existing products. I have not found this with the EAH pipeline. It may well be that I have looked in the wrong place and/or it will be in the Annual Report or Capital Markets Day. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
